Gaithersburg, Maryland – October 30, 2018: MaxCyte announced today that Debra K. Bowes, Chief Business Officer, CARMA Cell Therapy, will present “Novel mRNA-based Autologous CAR Therapies in Oncology” at the 24th Annual International Partnering Conference BIO-EUROPE. The Conference takes place November 5-7, 2018 at the Bella Center Copenhagen.
Ms. Bowes will discuss MaxCyte’s next-generation autologous CAR (chimeric antigen receptor) therapies on November 6 at 10:45 a.m. CEST as part of the conference’s Cell and Gene Track. She will highlight how MaxCyte’s breakthrough CARMA platform in immuno-oncology has the ability to engineer transient persistence that may potentially mitigate off-tumor toxicity and significantly reduce the turnaround time for delivery of autologous cell therapy to patients.
“I always appreciate the opportunity to discuss our CARMA platform’s potential in a broad range of targets and cancers, including solid tumors, and look forward to doing so at BIO-EUROPE next month,” said Ms. Bowes. “Our novel CAR construct is engineered with the intention of reducing potential adverse events that have been evident with previous CAR technologies. This is significant, now more than ever, as we recently began dosing patients in our first clinical study with our first wholly-owned lead CAR therapeutic candidate, MCY-M11.”
Investigators are currently evaluating the safety and effectiveness of intraperitoneal infusions of MCY-M11 in a multi-center, non-randomized, open label, dose-escalation Phase I clinical trial in individuals with ovarian cancer and peritoneal mesothelioma. More information about the study can be found at ClinicalTrials.gov.
MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte’s mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation® Technology to enable its partners across the biopharmaceutical industry to advance the development of innovative medicines, particularly in cell therapy, including gene editing and immuno-oncology. The Company has placed its cutting-edge flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies, has more than 55 partnered program licenses in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products. For more information visit www.maxcyte.com
|For further information, please contact: